Related Experiment Video
Updated: May 22, 2025
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Enhanced sequential osteosarcoma therapy using a 3D-Printed bioceramic scaffold combined with 2D nanosheets via
Guangyu Jian1, Si Wang1, Xinlu Wang1
1The Affiliated Stomatological Hospital of Chongqing Medical University, Chongqing Key Laboratory of Oral Diseases, Chongqing Municipal Key aboratory of Oral Biomedical Engineering of Higher Education, Chongqing Municipal Health Commission Key Laboratory of Oral Biomedical Engineering, Chongqing, 401147, PR China.
Background:
Osteosarcoma (OS) is a malignant tumor originating from primitive mesenchymal cells, characterized by rapid metastasis, high invasiveness, and significant mortality. The primary challenges in OS management include the effective elimination of residual tumor cells to prevent recurrence and the repair of extensive bone defects caused by surgical intervention.
Objective:
This study aims to develop an innovative biomimetic 3D-printed bioactive glass ceramic (BGC) scaffold modified with two-dimensional nanosheets to address both tumor ablation and bone tissue repair.
Materials And Methods:
The nanosheets were constructed via ellagic acid (EA) and ruthenium (Ru) coordination, leveraging the non-topological adhesion properties of catechol in EA to deposit the nanosheets onto the BGC scaffold (EARu-BGC). The therapeutic effects of EARu-BGC were evaluated in vitro and in vivo.
Results:
EARu-BGC sequentially responds to the local microenvironment during OS treatment. During the tumor ablation phase, EARu-BGC induced ferroptosis through the synergistic effects of photothermal and chemodynamic therapy, achieving over 90 % tumor cell ablation and significantly inhibiting tumor volume and weight. In the bone tissue repair phase, EARu-BGC exhibited adaptive ROS scavenging and facilitated a pro-healing microenvironment, promoting osteogenic differentiation. The gradual degradation of the BGC scaffold provided essential minerals and space for new bone formation. In vivo experiments demonstrated that EARu-BGC significantly enhanced osteogenesis, increasing the trabecular number to 1.51 ± 0.15/mm and reducing trabecular separation to 1.50 ± 0.04 mm.
Conclusion:
The EARu-BGC scaffold presents a promising multifunctional platform for OS treatment by effectively balancing antitumor efficacy with bone repair capabilities.
Insights
This study developed a novel biomimetic scaffold (EARu-BGC) for osteosarcoma treatment. The scaffold effectively eliminates tumor cells and promotes bone repair, offering a promising dual-action therapy.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Oncology
- Regenerative Medicine
Background:
- Osteosarcoma (OS) is a highly aggressive bone cancer with poor prognosis.
- Current challenges include preventing recurrence and repairing bone defects post-surgery.
- Effective treatments require addressing both tumor ablation and bone regeneration.
Purpose of the Study:
- To develop a 3D-printed bioactive glass ceramic (BGC) scaffold modified with ellagic acid and ruthenium (Ru) nanosheets (EARu-BGC).
- To evaluate the dual therapeutic potential of EARu-BGC for osteosarcoma treatment and bone tissue repair.
- To investigate the scaffold's response to the tumor microenvironment for sequential therapeutic effects.
Main Methods:
- Fabrication of EARu-BGC scaffolds using 3D printing and coordination of ellagic acid (EA) with ruthenium (Ru).
- In vitro and in vivo evaluation of the scaffold's antitumor and bone regenerative properties.
- Assessment of ferroptosis induction via photothermal and chemodynamic therapy for tumor ablation.
Main Results:
- EARu-BGC achieved over 90% osteosarcoma cell ablation by inducing ferroptosis.
- The scaffold demonstrated adaptive reactive oxygen species (ROS) scavenging, promoting a pro-healing microenvironment.
- In vivo studies showed enhanced osteogenesis, significantly increasing trabecular bone formation.
Conclusions:
- EARu-BGC is a multifunctional platform for osteosarcoma treatment.
- The scaffold effectively balances antitumor activity with bone repair capabilities.
- This innovative biomaterial shows promise for improving outcomes in osteosarcoma patients.
